Dong ZHANG, Yi-bo MA, Hua-ni PANG, Fu YI. Safety and efficacy of dabigatran (110mg) in cryoballoon ablation[J]. Chinese Heart Journal, 2022, 34(4): 394-398, 407. DOI: 10.12125/j.chj.202111089
    Citation: Dong ZHANG, Yi-bo MA, Hua-ni PANG, Fu YI. Safety and efficacy of dabigatran (110mg) in cryoballoon ablation[J]. Chinese Heart Journal, 2022, 34(4): 394-398, 407. DOI: 10.12125/j.chj.202111089

    Safety and efficacy of dabigatran (110mg) in cryoballoon ablation

    •   AIM  To explore the safety and efficacy of dabigatran 110 mg in the periprocedural period and 1 year follow-up after cryoballoon ablation procedure for atrial fibrillation.
        METHODS  We performed a prospective study involving patients with drug-refractory, paroxysmal or persistent atrial fibrillation who underwent cryoballoon ablation procedure in the Department of Cardiology, the First Affiliated Hospital of Air Force Medical University from January 2018 to June 2019. All patients received 110 mg of darigatran bid during the periprocedural period. Subsequent outpatient follow-up was conducted for 1 year and relevant clinical data were collected. Thromboembolic and hemorrhagic events associated with drug use were analyzed, and multivariate logistic regression analysis was used to identify possible relevant factors.
        RESULTS  A total of 148 patients who underwent cryoballoon ablation met the criteria and were included in this study, none of whom experienced clinical thromboembolism or massive bleeding events within the one-year follow-up. The overall success rate of cryoballoon ablation was 77.70%. Mild bleeding events occurred in 22 patients (14.9%) in the blanking period (3 months) and no complications related to drug application were found after 12 weeks. Acute pericardial tamponade occurred in 1 patient during the periprocedural period. Multivariate logistic regression analysis showed that a history of hypertension was the only risk factor for mild bleeding events (P<0.05).
        CONCLUSION  Dabigatran given at a dose of 110 mg bid is safe and effective during perioperative period and one-year follow-up after cryoballoon ablation for atrial fibrillation. No thromboembolism or drug-related major bleeding events are observed in this study. Mild bleeding is common, especially in patients with a history of hypertension, but these events occur in the blanking period.
    • loading

    Catalog

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return